Literature DB >> 18807120

Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient.

Laura Scaramucci1, Pasquale Niscola2, Micaela Ales2, Marco Giovannini2, Andrea Tendas2, Luca Cupelli2, Agostina Siniscalchi2, Daniela Piccioni2, Teresa Dentamaro2, Alessio Perrotti2, Paolo de Fabritiis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18807120     DOI： 10.1007/s12185-008-0161-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

1.  The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

Authors:  F Willis; J C Marsh; D H Bevan; S B Killick; G Lucas; R Griffiths; W Ouwehand; G Hale; H Waldmann; E C Gordon-Smith
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

2.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Authors:  M Zecca; P De Stefano; B Nobili; F Locatelli
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

3.  Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.

Authors:  M Dungarwalla; J C W Marsh; J A Tooze; G Lucas; W Ouwehand; R Pettengell; C E Dearden; E C Gordon Smith; M O Elebute
Journal:  Ann Hematol       Date:  2006-11-23       Impact factor: 3.673

4.  Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.

Authors:  Giovanni D'Arena; Catello Califano; Mario Annunziata; Alfredo Tartarone; Silvana Capalbo; Oreste Villani; Giovanni Amendola; Giuseppe Pietrantuono; Felicetto Ferrara; Antonio Pinto; Pellegrino Musto; Alfonso Maria D'Arco; Nicola Cascavilla
Journal:  Eur J Haematol       Date:  2007-05-28       Impact factor: 2.997

5.  Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.

Authors:  Ken-ichi Sawada; Makoto Hirokawa; Naohito Fujishima; Masanao Teramura; Masami Bessho; Kazuo Dan; Hisashi Tsurumi; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Keiya Ozawa
Journal:  Haematologica       Date:  2007-07-20       Impact factor: 9.941
  5 in total
  1 in total

1.  Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.

Authors:  Andrea Tendas; Pasquale Niscola; Laura Scaramucci; Luca Cupelli; Alessio Pio Perrotti; Paolo de Fabritiis
Journal:  Blood Res       Date:  2016-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.